临床荟萃

• 论著 • 上一篇    下一篇

沙利度胺治疗结缔组织病相关肺间质疾病的临床观察

  

  1. 甘肃省人民医院  风湿免疫科,甘肃 兰州 730000
  • 出版日期:2019-07-20 发布日期:2019-08-24
  • 通讯作者: 周淑红,Email: zshlz1973@126.com
  • 基金资助:
    甘肃省青年科技基金项目----艾拉莫德在系统性红斑狼疮肾炎中调控信号通路Pin1/Smurf1的机制研究(17JR5RA032)

Clinical observation of thalidomide in treatment of connective tissue  disease associated interstitial lung disease

  1. Department of Rheumatology and Immunology,  Gansu Provincial People's Hospital,  Lanzhou 730000, China
  • Online:2019-07-20 Published:2019-08-24
  • Contact: Corresponding author: Zhou Shuhong, Email: zshlz1973@126.com

摘要: 目的评估激素联合沙利度胺治疗结缔组织病肺间质纤维化(CTDILD)的有效性及安全性。方法将66例患者随机分为两组:对照组予醋酸泼尼松等常规治疗,联合组在上述基础上口服沙利度胺,疗程为6个月。结果联合组患者临床症状、肺功能、肺CT改善程度均优于对照组(P<0.05)。治疗过程中,两组患者不良反应发生情况无显著差异(P>0.05)。结论沙利度胺治疗CTDILD能够提高治疗效果,且无明显不良反应。

关键词: 混合性结缔组织病, 肺疾病,  , 间质性, 药物疗法,  , 联合

Abstract: Objective  To evaluate the efficacy and safety of steroid combined with thalidomide in the treatment of connective tissue disease with interstitial lung fibrosis (CTDILD). Methods  Sixtysix patients were randomly divided into two groups:  control group was given prednisone acetate  and other routine treatment. The combined group took thalidomide  more,  and the course of treatment was six months. Results   The clinical symptoms,  pulmonary function and pulmonary CT improvement in combined group were better than those in control group (P<0.05). In the course of treatment,  there was no significant difference in the incidence of adverse reactions between  two groups (P>0.05). Conclusion  Thalidomide in the treatment of CTDILD can improve the therapeutic effect and has no obvious adverse reactions.

Key words: mixed connective tissue disease;lung disease, , interstitial;drug therapy, , combination